Press releaseUpsher-Smith Completes Sale of Two Migraine Products


PDF File

Maple Grove, MN – June 30, 2023 – Upsher-Smith Laboratories, LLC (Upsher-Smith, President and COO: Rich Fisher), a subsidiary of Sawai Group Holdings Co., Ltd. (Sawai, Head office:Osaka, Japan, President: Mitsuo Sawai) announced the completion of its previously-announced sale of Zembrace® SymTouch® (sumatriptan injection) 3 mg and Tosymra® (sumatriptan nasal spray) 10 mg to Tonix Medicines, Inc. (Head Office: Chatham, NJ, President: James Hunter), the wholly owned subsidiary of Tonix Pharmaceuticals Holding Corp. (Tonix Pharmaceuticals, Head Office: Chatham, NJ, CEO & Chairman: Seth Lederman)

About Tonix Pharmaceuticals

Tonix is a biopharmaceutical company focused on discovering, licensing, acquiring, developing, and marketing therapeutics to treat and prevent human disease and alleviate suffering. Tonix’s portfolio is composed of central nervous system (CNS), rare disease, immunology and infectious disease product candidates. For more information, visit


About Upsher-Smith

Upsher-Smith Laboratories, LLC is a trusted U.S. pharmaceutical company that strives to improve the health and lives of patients through an unwavering commitment to high-quality products and sustainable growth. The company brings brands and generics to a wide array of customers, always backed by its attentive level of service, strong industry relationships, and dedication to uninterrupted supply. For more information, visit

Back to the list